Current and future medical treatments for patients with acromegaly

References

• Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151:439–446.
   PubMed Web of Science ®Google Scholar
• Sesmilo G. Epidemiology of acromegaly in Spain. Endocrinol Nutr. 2013;60:470–474.
   PubMed Web of Science ®Google Scholar
• Bex M, Abs R, T’Sjoen G, et al. AcroBel--the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur J Endocrinol. 2007;157:399–409.
   PubMed Web of Science ®Google Scholar
• Reincke M, Petersenn S, Buchfelder M, et al. The German acromegaly registry: description of the database and initial results. Exp Clin Endocrinol Diabetes. 2006;114:498–505.
   PubMed Web of Science ®Google Scholar
• Arosio M, Reimondo G, Malchiodi E, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167:189–198.
   PubMed Web of Science ®Google Scholar
• Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010 Mar;72:377–382.
   PubMed Web of Science ®Google Scholar
• Hoskuldsdottir GT, Fjalldal SB, Sigurjonsdottir HA. The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013. Pituitary. 2015;18:803–807.
   PubMed Web of Science ®Google Scholar
• Tjornstrand A, Gunnarsson K, Evert M, et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur J Endocrinol. 2014;171:519–526.
   PubMed Web of Science ®Google Scholar
• Burton T, Le Nestour E, Neary M, et al. Incidence and prevalence of acromegaly in a large US health plan database. Pituitary. 2016;19:262–267.
   PubMed Web of Science ®Google Scholar
• Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93:61–67.
   PubMed Web of Science ®Google Scholar
• Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 1994;41:95–102.
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89:667–674.
   PubMed Web of Science ®Google Scholar
• Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab. 2005;90:4081–4086.
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Cavagnini F, et al. Acromegaly treatment consensus workshop participants. Guidelines for acromegaly management. J Clin Endocrinol Metab. 2002;87:4054–4058.
   PubMed Web of Science ®Google Scholar
• Katznelson L, Laws ER Jr., Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933–3951.
   PubMed Web of Science ®Google Scholar
• Giustina A, Casanueva FF, Cavagnini F, et al. Pituitary Society and the European Neuroendocrine Association. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest. 2003;26:1242–1247.
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16:294–302.
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Maffezzoni F, et al. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. Expert Opin Investig Drugs. 2014;23:1619–1635.
   PubMed Web of Science ®Google Scholar
• González B, Vargas G, Espinosa-de-los-Monteros AL, et al. Efficacy and safety of radiotherapy in acromegaly. Arch Med Res. 2011;42:48–52.
   PubMed Web of Science ®Google Scholar
• Barkan AL, Halasz I, Dornfeld KJ, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab. 1997;82:3187–3191.
   PubMed Web of Science ®Google Scholar
• Barrande G, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab. 2000;85:3779–3785.
   PubMed Web of Science ®Google Scholar
• Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab. 2004;89:1613–1617.
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Marzullo P, Doga M, et al. Growth hormone deficiency in treated acromegaly. Trends Endocrinol Metab. 2015;26:11–21.
   PubMed Web of Science ®Google Scholar
• Marazuela M, Ramos-Leví A, Sampedro-Núñez M, et al. Cabergoline treatment in acromegaly: pros. Endocrine. 2014;46:215–219.
   PubMed Web of Science ®Google Scholar
• Kasuki L, Vieira Neto L, Gadelha MR. Cabergoline treatment in acromegaly: cons. Endocrine. 2014;46:220–225.
   PubMed Web of Science ®Google Scholar
• Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96:1327–1335.
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Pivonello R, Ferreri L, et al. Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin North Am. 2015 Mar;44(1):89–97.
   PubMed Web of Science ®Google Scholar
• Reichlin S. Somatostatin. N Engl J Med. 1983;309:1495–1501.
   PubMed Web of Science ®Google Scholar
• Csaba Z, Dournaud P. Cellular biology of somatostatin receptors. Neuropeptides. 2001;35:1–23.
   PubMed Web of Science ®Google Scholar
• Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev. 1995;16:427–442.
   PubMed Web of Science ®Google Scholar
• Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–198.
   PubMed Web of Science ®Google Scholar
• Giustina A, Karamouzis I, Patelli I, et al. Octreotide for acromegaly treatment: a reappraisal. Expert Opin Pharmacother. 2013;14:2433–2447.
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkan A, Chanson P, et al. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest. 2008;31:820–838.
   PubMed Web of Science ®Google Scholar
• Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metabolism. 2008;93:2957–2968.
   PubMed Web of Science ®Google Scholar
• Roelfsema F, Biermasz NR1, Pereira AM, et al. Optimizing blood sampling protocols in patients with acromegaly for the estimation of growth hormone secretion. J Clin Endocrinol Metab. 2016;29:jc20161142.
   Google Scholar
• Espinosa-de-los-Monteros AL, Gonzalez B, Vargas G, et al. Octreotide LAR treatment of acromegaly in “real life”: long-term outcome at a tertiary care center. Pituitary. 2015;18:290–296.
   PubMed Web of Science ®Google Scholar
• Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90:4465–4473.
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol. 2007;157:579–587.
   PubMed Web of Science ®Google Scholar
• Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomized controlled trial. Eur J Endocrinol. 2009;161:331–338.
   PubMed Web of Science ®Google Scholar
• Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of growth hormone secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2006;91:85–92.
   PubMed Web of Science ®Google Scholar
• Vilar L, Fleseriu M, Naves LA, et al. Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial. Endocrine. 2014;46:577–584.
   PubMed Web of Science ®Google Scholar
• Plöckinger U, Dienemann D, Quabbe HJ. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab. 1990;71:1658–1662.
   PubMed Web of Science ®Google Scholar
• Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol. 2004;151:317–324.
   PubMed Web of Science ®Google Scholar
• Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2002;87:3013–3018.
   PubMed Web of Science ®Google Scholar
• Florio T, Schettini G. Multiple intracellular effectors modulate physiological functions of the cloned somatostatin receptors. J Mol Endocrinol. 1996;17:89–100.
   PubMed Web of Science ®Google Scholar
• Reardon DB, Wood SL, Brautigan DL, et al. Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatin. Biochem J. 1996;314:401–404.
   PubMed Web of Science ®Google Scholar
• Florio T, Thellung S, Arena S, et al. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol. 1999;141:396–408.
   PubMed Web of Science ®Google Scholar
• Cheung NW, Boyages SC. Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block. Endocrinology. 1995;136:4174–4181.
   PubMed Web of Science ®Google Scholar
• Ferrante E, Pellegrini C, Bondioni S, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer. 2006;13:955–962.
   PubMed Web of Science ®Google Scholar
• Teijeiro R, Rios R, Costoya JA, et al. Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem. 2002;12:31–38.
   PubMed Web of Science ®Google Scholar
• Thangaraju M, Sharma K, Leber B, et al. Regulation of acidification and apoptosis by SHP-1 and Bcl-2. J Biol Chem. 1999;274:29549–29557.
   PubMed Web of Science ®Google Scholar
• Lin CY, Varma MG, Joubel A, et al. Conserved motifs in somatostatin, D2-dopamine, and alpha 2B-adrenergic receptors for inhibiting the Na-H exchanger, NHE1. J Biol Chem. 2003;278:15128–15135.
   PubMed Web of Science ®Google Scholar
• Buchan AM, Lin CY, Choi J, et al. Somatostatin, acting at receptor subtype 1, inhibits Rho activity, the assembly of actin stress fibers, and cell migration. J Biol Chem. 2002;277:28431–28438.
   PubMed Web of Science ®Google Scholar
• Bousquet C, Guillermet-Guibert J, Saint-Laurent N, et al. Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. Embo J. 2006;25:3943–3954.
   PubMed Web of Science ®Google Scholar
• Pagotto U, Arzberger T, Ciani E, et al. Inhibition of Zac1, a new gene differentially expressed in the anterior pituitary, increases cell proliferation. Endocrinology. 1999;140:987–996.
   PubMed Web of Science ®Google Scholar
• Murray RD, Kim K, Ren SG, et al. Central and peripheral actions of somatostatin on the growth hormone – IGF-I axis. J Clin Invest. 2004;114:349–356.
   PubMed Web of Science ®Google Scholar
• Bocci G, Culler MD, Fioravanti A, et al. In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists. Eur J Clin Invest. 2007;37:700–708.
   PubMed Web of Science ®Google Scholar
• Florio T, Morini M, Villa V, et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology. 2003;144:1574–1584.
   PubMed Web of Science ®Google Scholar
• Patel PC, Barrie R, Hill N, et al. Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery. 1994;116:1148–1152.
   PubMed Web of Science ®Google Scholar
• Barrie R, Woltering EA, Hajarizadeh H, et al. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res. 1993;55:446–450.
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary. 2010;13:60–67.
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Torri V, et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One. 2012;7:e36411.
   PubMed Web of Science ®Google Scholar
• Caron PJ, Bevan JS, Petersenn S, et al. Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99:1282–1290.
   PubMed Web of Science ®Google Scholar
• Kopchick JJ, Parkinson C, Stevens EC, et al. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev. 2002;23:623–646.
   PubMed Web of Science ®Google Scholar
• Giustina A, Ambrosio MR, Beck-Peccoz P, et al. Use of pegvisomant in acromegaly. An Italian society of endocrinology guideline. J Endocrinol Invest. 2014;37:1017–1030.
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Hutson RK, Trainer PJ, et al. Long term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358:1754–1759.
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England J Med. 2000;342:1171–1177.
   PubMed Web of Science ®Google Scholar
• Buchfelder M, Schlaffer S, Droste M, et al. The German ACROSTUDY: past and present. Eur J Endocrinol. 2009;161(Suppl):S3–S10.
   PubMed Web of Science ®Google Scholar
• Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol. 2007;156:75–82.
   PubMed Web of Science ®Google Scholar
• Grottoli S, Maffei P, Bogazzi F, et al. ACROSTUDY: the Italian experience. Endocrine. 2015;48:334–341.
   PubMed Web of Science ®Google Scholar
• Giustina A. Optimal use of pegvisomant in acromegaly: are we getting there? Endocrine. 2015;48:3–8.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, Franck SE, de Rooij FW, et al. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2014;99:3644–3652.
   PubMed Web of Science ®Google Scholar
• Buhk JH, Jung S, Psychogios MN, et al. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab. 2010;95:552–558.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van Aken MO, Janssen JA, et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab. 2007;92:4598–4601.
   PubMed Web of Science ®Google Scholar
• Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet. 2005;365:1644–1646.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, de Herder WW, Janssen JA, et al. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-termsafety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol. 2009;160:529–533.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab. 2008;93:3853–3859.
   PubMed Web of Science ®Google Scholar
• Tuvia S, Salama P, Weinstein I, et al. Octreolin a safe oral alternative for parenteral octreotide treatment. Growth Horm IGF Res. 2010;20:S35–S36.
   Google Scholar
• Tuvia S, Atsmon J, Teichman SL, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab. 2012;97:1–8.
   PubMed Web of Science ®Google Scholar
• Melmed S, Popovic V, Bidlingmaier M, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab. 2015;100:1699–1708.
   PubMed Web of Science ®Google Scholar
• Chiasma provides update regarding FDA’s complete response letter for Mycapssa™ new drug application [Internet]. [cited 2016 May 6]. Available from: https://globenewswire.com/news-release/2016/04/18/829612/0/en/
   Google Scholar
• Maggio ET, Grasso P. Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice. Regul Pept. 2011;167:233–238.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Chieffo C, Bai SA, et al. A subcutaneous octreotide hydrogel implant for the treatment of acromegay. Endocr Pract. 2012;18:870–881.
   PubMed Web of Science ®Google Scholar
• Chieffo C, Cook D, Xiang Q, et al. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. J Clin Endocrinol Metab. 2013;98:4047–4054.
   PubMed Web of Science ®Google Scholar
• Tiberg F, Roberts J, Cervin C, et al. Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers. Br J Clin Pharmacol. 2015;80:460–472.
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A. Pharmacotherapy for acromegaly: future role for pasireotide? Endocrinol Metab Clin North Am. 2015;44:35–41.
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99:791–799.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide C2402 study group. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomized, phase 3 trial. Lancet Diabetes Endocrinol. 2014;11:875–884.
   Web of Science ®Google Scholar
• Giustina A, Chanson P, Bronstein MD, et al. Acromegaly consensus group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95:3141–3148.
   PubMed Web of Science ®Google Scholar
• Petersenn S, Farrall AJ, De Block C, et al. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary. 2013;14:132–140.
   Google Scholar
• Petersenn S, Bollerslev J, Arafat AM, et al. Pharmacokinetics, pharmacodynamics and safety of Pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. J Clin Pharmacol. 2014;54:1308–1317.
   PubMed Web of Science ®Google Scholar
• Schmid HA, Brue T, Colao A, et al. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine. 2016. doi:10.1007/s12020-016-0895-8.
   PubMed Web of Science ®Google Scholar
• Frara S, Maffezzoni F, Mazziotti G, et al. Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab. 2016 May 24; pii: S1043-2760(16)30041-8. doi:10.1016/j.tem.2016.04.014.
   PubMedGoogle Scholar
• Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab. 2011;22:499–506.
   PubMed Web of Science ®Google Scholar
• Colao A, De Block C, Gaztambide MS, et al. Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary. 2014;17:180–186.
   PubMed Web of Science ®Google Scholar
• ITF2984 Repeated doses study in healthy volunteers (MAD) [Internet]. [cited 2016 Apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01871844?term=itf2984&rank=3
   Google Scholar
• A two part phase 1, repeated doses and continuous infusion study with ITF2984 in healthy volunteers (14 days MAD) [Internet]. [cited 2016 Apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01897844?term=itf2984&rank=2
   Google Scholar
• Phase II study with ITF2984 in acromegalic patients (POC) [Internet]. [cited 2016 Apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02111044?term=itf2984&rank=1
   Google Scholar
• Afargan M, Janson ET, Gelerman G, et al. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology. 2001;142:477–486.
   PubMed Web of Science ®Google Scholar
• Shimon I, Rubinek T, Hadani M, et al. PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion. J Endocrinol Invest. 2004;27:721–727.
   PubMed Web of Science ®Google Scholar
• Plockinger U, Hoffmann U, Geese M, et al. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. Eur J Endocrinol. 2012;166:223–234.
   PubMed Web of Science ®Google Scholar
• Aspireo Pharma website. [cited 2016 Mar 20]. Available from: http://www.aspireopharma.com/ somatoprim.
   Google Scholar
• Somm E, Bonnet N, Zizzari P, et al. Comparative inhibition of the GH/IGF-I axis obtained with either the targeted secretion inhibitor SXN101959 or the somatostatin analog octreotide in growing male rats. Endocrinology. 2013;154:4237–4248.
   PubMed Web of Science ®Google Scholar
• Tachas G, Lofthouse S, Wraight CJ, et al. A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal mice. J Endocrinol. 2006;189:147–154.
   PubMed Web of Science ®Google Scholar
• Wilkinson-Berka JL, Lofthouse S, Jaworski K, et al. An antisense oligonucleotide targeting the growth hormone receptor inhibits neovascularization in a mouse model of retinopathy. Mol Vis. 2007;13:1529–1538.
   PubMed Web of Science ®Google Scholar
• Trainer P, Newell-Price J, Ayuk J, et al. A phase 2 study of antisense oligonucleotide therapy directed at the GH receptor demonstrates lowering of serum IGF1 in patients with acromegaly. Endocrine Abstracts. 2015; 37 GP19.10. doi:10.1530/endoabs.37.GP.19.10.
   Google Scholar
• ATL1103 for growth and sight disorders [Internet]. [cited 2016 Mar 20]. Available from: http://www.antisense.com.au/atl1103
   Google Scholar
• Pipeline preclinical studies for rare and severe diseases [Internet]. [cited 2016 Mar 13]. Available from: http://www.ionispharma.com/preclinical/
   Google Scholar
• Nachtigall L, Delgado A, Swearingen B, et al. Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab. 2008;93:2035–2041.
   Google Scholar
• Giustina A, Chanson P, Kleinberg D, et al. A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10:243–248.
   PubMed Web of Science ®Google Scholar
• Carmichael JD, Bonert VS, Nuño M, et al. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014;99:1825–1833.
   PubMed Web of Science ®Google Scholar
• Gola M, Bonadonna S, Mazziotti G, et al. Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest. 2006;29:86–93.
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Porcelli T, Bogazzi F, et al. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol. 2011;164:341–347.
   PubMed Web of Science ®Google Scholar
• Giustina A, Bevan JS, Bronstein MD, et al. SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study. Pituitary. 2016;19:39–49.
   PubMed Web of Science ®Google Scholar